OncoSec Medical Inc (ONCSQ)

[hschlauch]

Imagine sustained expression of anti-pd1, anti-pdl1, anti-ctla-4, anti-tim-3, - virtually any monoclonal antibody - in tumor microenvironments...

Now imagine those antibodies being delivered by ONCS's new electroporation device, which as we learned now has several pending patent applications.

Prime an immune response using electroporated and DNA-encoded chemokines, TLR agonists, Co-stimulatory molecules, professional antigen presenting cells, and IL-12 prior to delivery of DNA encoded antibodies. Guess what happens when you successfully express all of those therapeutic agents in tumor microenvironments...

I read a report somewhere that checkpoint inhibitors may collectively exceed $50B in peak sales by 2025.

I think this is what PD was referring to when he kept mentioning value creation.